|
 
 |
| EDITORIAL |
|
| Year : 2019 | Volume
: 1
| Issue : 1 | Page : 2-3 |
|
Translational Critical Care Medicine: Integrating State-of-the-Art Knowledge between Bench and Bedside
Xiaofeng Jia1, Zhiyong Peng2
1 Department of Neurosurgery; Department of Orthopaedics; Department of Anatomy and Neurobiology, University of Maryland School of Medicine; Department of Biomedical Engineering; Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2 Department of Intensive Care Unit, Zhongnan Hospital of Wuhan University, Wuhan, China; Department of Critical Care Medicine, Center of Critical Care Nephrology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
| Date of Web Publication | 4-Jan-2019 |
Correspondence Address:
Prof. Xiaofeng Jia
685 West Baltimore Street, MSTF 823, Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21201
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jtccm.jtccm_18_18
How to cite this article:
Jia X, Peng Z. Translational Critical Care Medicine: Integrating State-of-the-Art Knowledge between Bench and Bedside. J Transl Crit Care Med 2019;1:2-3 |
How to cite this URL:
Jia X, Peng Z. Translational Critical Care Medicine: Integrating State-of-the-Art Knowledge between Bench and Bedside. J Transl Crit Care Med [serial online] 2019 [cited 2023 Mar 31];1:2-3. Available from: http://www.tccmjournal.com/text.asp?2019/1/1/2/249334 |
With rapid development in the past few decades, critical care medicine and the intensive care unit (ICU) have become irreplaceable parts of the healthcare system. It is a multidisciplinary system that provides specialized and intensive medical care, advanced monitoring, organ function maintenance, and life support for critically ill patients. During the Crimean War in 1854, Florence Nightingale and a team of nurses provided intensive nursing care for critically injured soldiers, and her model of care was considered the precursor of contemporary ICUs. The first ICU was established in Denmark in 1953 when polio became epidemic and patients were centralized in a discrete department and mechanical ventilation was used to support the victims. Since then, critical care medicine continued embracing fast-developing technologies for organ maintenance and life support such as electrocardiogram monitoring, invasive mechanical ventilation, hemodialysis, bedside ultrasound, and extracorporeal membrane oxygenation. Nowadays, critical care medicine has become an integral element of the healthcare systems worldwide and has been evolved into a distinct medical subspecialty. To continue the advancement of critical care medicine, physicians and scientists must not only focus on developing novel medical technologies but also integrate knowledge from clinical and basic science research to further our treatment of critically ill patients.
Translational Medicine is a new concept emerging in the international medical field in recent decades. In 1992, SCIENCE first came up with the concept of “bench to bedside.”[1] The use of “translational medicine” first appeared in LANCET in 1996.[2] In 2003, the published article The NIH Roadmap on Science caused the academic community to attach great importance to translational research.[3] Translational medicine is the process of rapidly and effectively transforming the latest achievements of basic biological research into clinical medical technology (bench to bedside) and using clinical results and experiences to drive research endeavors in the laboratory (bedside to bench). Translational medicine is a highly interdisciplinary field combining both theory and practice and covering crucial steps from bench to bedside to facilitate the characterization of disease model and application of new medical interventions.[4] The initial goals were to break the barrier between basic research and clinical medicine, to hasten the transition of basic research achievements to clinical therapeutic applications, and to ultimately improve patient outcomes and guide government public health policy. The development translational medicine has received increasing attention from scholars worldwide.
Given the importance of translational research in critical care medicine, The Journal of Translational Critical Care Medicine (JTCCM) has been established in 2018. This journal aims to bridge the gap between basic pathogenesis research and clinical treatment application, to allow a better understanding of basic mechanisms of diseases by clinicians, and to achieve the transition from basic critical care research to clinical application. In accordance with this aim, articles related to translational medicine in critical care will be prioritized in our magazine. At the same time, papers of all aspects of critical care medicine are welcomed including emergency medicine, multiple organ dysfunction syndromes, trauma, burn, acute kidney injury, acute lung injury, and severe acute pancreatitis. The journal will also cover fundamental researches and development of new technologies in clinical practice. As to the format, we accept research articles, reviews, case reports, guidelines, letter to the editor, and new technology. Another mission of this journal is to construct a platform for international scientific and clinical communities to allow academic exchanges, discussions, inspirations, and innovations. JTCCM is an open-access peer-reviewed quarterly publication that allows articles to be freely downloaded, thus facilitating the dissemination of ideas and new discoveries. Finally, on behalf of editors and expert team at JTCCM, we would like to express our sincere gratitude – thank you for your support of JTCCM. We believe that a dedicated journal for translational research in critical medicine has been long overdue, and we are confident that with our collective efforts, JTCCM will become a highly appreciated publication of knowledge and technology around the world. We wish JTCCM a bright future!
Acknowledgment
XJ is partially supported by Maryland Stem Cell Research Fund, USA (2018-MSCRFD-4271) (to XJ), and R01HL118084 and R01NS110387 from United States National Institutes of Health (both to XJ).
| References | |  |
| 1. | Choi DW. Bench to bedside: The glutamate connection. Science 1992;258:241-3.  |
| 2. | Geraghty J. Adenomatous polyposis coli and translational medicine. Lancet 1996;348:422. |
| 3. | Zerhouni E. Medicine. The NIH roadmap. Science 2003;302:63-72. |
| 4. | Jia X. Translational medicine: Creating the crucial bidirectional bridge between bench and bedside. Int J Mol Sci 2016;17. pii: E1918. |
|
Search Pubmed for